Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Department of Oncology Surgery, Shantou Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ann Surg Oncol. 2021 Oct;28(11):6341-6352. doi: 10.1245/s10434-020-09509-z. Epub 2021 Mar 18.
Nodal-skip metastasis (NSM) is found in esophageal squamous cell carcinoma (ESCC), but its prognostic role is controversial. This study aimed to investigate the prognostic value of NSM for thoracic ESCC patients.
Categorization of NSM was according to the N groupings of Japan Esophagus Society (JES) staging system, which is dependent on tumor location. Using the Kaplan-Meier method and Cox-regression analysis, this study retrospectively analyzed the overall survival (OS) for 2325 ESCC patients after radical esophagectomy at three high-volume esophageal cancer centers. Predictive models also were constructed.
The overall NSM rate was 20% (229/1141): 37.4% in the in upper, 12.9% in the middle, and 22.2% in the lower thoracic ESCC. The patients with NSM always had a better prognosis than those without NSM. Furthermore, NSM was an independent prognostic factor for thoracic ESCC patients (hazard ratio [HR], 0.633; 95% confidence interval [CI], 0.499-0.803; P < 0.001). By integrating the prognostic values of NSM and N stage, the authors proposed the new N staging system. The categories defined by the new N staging system were more homogeneous in terms of OS than those defined by the current N system. Moreover, the new N system was shown to be an independent prognostic factor also for thoracic ESCC patients (HR, 1.607; 95% CI, 1.520-1.700; P < 0.001). Overall, the new N system had slightly better homogeneity, discriminatory ability, and monotonicity of gradient than the current N system.
This study emphasized the prognostic power of NSM and developed a modified node-staging system to improve the efficiency of the current International Union for Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) N staging system.
跳跃性淋巴结转移(NSM)可见于食管鳞状细胞癌(ESCC),但其预后作用仍存在争议。本研究旨在探讨 NSM 对胸段 ESCC 患者的预后价值。
根据日本食管学会(JES)分期系统的 N 分组对 NSM 进行分类,该系统依赖于肿瘤位置。本研究采用 Kaplan-Meier 法和 Cox 回归分析,对三家大容量食管癌中心行根治性食管切除术的 2325 例 ESCC 患者的总生存(OS)进行回顾性分析。还构建了预测模型。
总体 NSM 率为 20%(229/1141):上段 37.4%,中段 12.9%,下段 22.2%。有 NSM 的患者预后总是优于无 NSM 的患者。此外,NSM 是胸段 ESCC 患者的独立预后因素(风险比 [HR],0.633;95%置信区间 [CI],0.499-0.803;P<0.001)。通过整合 NSM 和 N 分期的预后价值,作者提出了新的 N 分期系统。与当前的 N 系统相比,新的 N 分期系统定义的类别在 OS 方面更具同质性。此外,新的 N 系统也是胸段 ESCC 患者的独立预后因素(HR,1.607;95%CI,1.520-1.700;P<0.001)。总体而言,新的 N 系统在同质性、区分能力和梯度单调性方面均略优于现行的 N 系统。
本研究强调了 NSM 的预后作用,并开发了改良的淋巴结分期系统,以提高现行国际抗癌联盟(UICC)/美国癌症联合委员会(AJCC)N 分期系统的效率。